Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Enzymatica AB: ColdZyme® sales continue to perform well

Enzymatica AB
Posted on: 03 Nov 16

Interim report for
Enzymatica AB (publ)
January-September 2016

ColdZyme ® sales continue to perform well

Q3

  • Net sales reached SEK 12.3 (6.8) million.
  • Loss after tax came in at SEK -6.5 (-10.1) million.
  • Earnings per share were SEK -0.08 (-0.41).
  • Cash and cash equivalents were SEK 49.9 (9.7) million.

Significant events in Q3

  • Enzymatica completed a directed share issue, raising SEK 40 million before issue expenses.

Significant events after Q3

  • Enzymatica signed exclusive agreements for Australia, New Zeeland, Greece and Cyprus.

First nine months

  • Net sales increased to SEK 25.6 (16.9) million.
  • Loss after tax came in at SEK -27.4 (-29.6) million.
  • Earnings per share were SEK -0.49 (-1.19).
Financial ratios          
(SEK million) Q3
2016
Q3
2015
Jan-Sep
2016
Jan-Sep
2015
Full year
2015
Net sales12.36.825.616.927.9
Gross margin, %6667647370
Operating profit/loss-7.7-9.9-27.6-29.4-40.5
Cash flow from operating activities-15.6-12.7 -35.6

 
-25.5-37.7
Average number of employees2217201516

(Zymetech is consolidated in Enzymatica's figures as at April 1, 2016)


CEO statement: Continued sales growth and new international agreements signed
The Company boasts year-on-year growth of 52% over the first nine months of the year, with total sales, including sales from Zymetech, coming in at SEK 25.6 million in comparison to SEK 16.9 million in the corresponding period of the previous year.  Sales in Sweden continue to perform well and in September ColdZyme® reported a market share of around 7% in the cold segment in spite of a weak start to the cold season. Growth in September was 81%. Other established markets are exhibiting satisfactory growth, except for the UK, where efforts to find a suitable distributor are in progress. Sales have gotten off to a good start on the Finnish market which was recently established, while pre-launch work in Spain is proceeding according to plan, with the expected start of the cold season in November.
The Company pursued its financing strategy in Q3 by conducting a directed issue of 17.5 million shares to new long-term and financially strong owners. The funds raised for the Company by the issue creates financial stability for the Company's ongoing international expansion.
Our efforts to reel in excellent distribution partners remain our highest priority, and we signed a distribution agreement for Greece and Cyprus in October. This agreement was signed with Life NLB Ltd, a small company prepared to put in the financial resources and commitment required to establish ColdZyme on these markets. Yesterday we signed a distribution agreement with Endeavour Consumer Health, Australia's largest distributor to pharmacies and the third largest in New Zealand. It is also our first contract in the southern hemisphere and a step towards a seasonal adjustment. We expect a launch in the 2018.
As previously announced, we expect to have the final results of our latest patient study ready by the end of the year. We are on track to meet higher government requirements in connection with the new EU legislation for medical devices on time. Adoption of the new legislation is expected early next year.
We enter the final chapter of 2016 with a boost from our sales growth and a  rise in demand for our product on the Scandinavian market.

Fredrik Lindberg, CEO


Enzymatica at a glance
Enzymatica AB is a life science company whose business concept is to develop medical devices based on barrier technology and marine enzymes for self-care in major market segments. The Company developed ColdZyme ® , a unique mouth spray for fighting colds, launched the product on seven markets and reached a position over the past winter as one of the most-sold cold products in Swedish pharmacies measured in SEK. Enzymatica has its own sales organization in Scandinavia and collaborates with a contract sales organization in the UK. Enzymatica also sells via distributers in Finland and Spain.

Our development focuses on medical devices for upper respiratory tract infections and oral health. An enzyme from deep-sea fish is a key sub-component in product development.

Enzymatica was founded in 2007, has its head office in Lund and has been listed on the Nasdaq First North since June 15, 2015.

For questions about this report, please contact:
Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com

Bengt Jöndell, Interim CFO, Enzymatica AB
Tel: +46 (0)703-77 71 70 | Email: bengt.jondell@enzymatica.com

Enzymatica Interim Report January-September 2016


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Enzymatica AB via GlobeNewswire
HUG#2053716
GlobeNewswire
globenewswire.com

Last updated on: 04/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.